ClinicalTrials.gg
CompletedNCT00129402Updated Feb 8, 2022Results posted

Effects of Ezetimibe With Simvastatin in the Therapy of Adolescents With HeFH (Study P02579)

A Phase 3 interventional study of ezetimibe with simvastatin and simvastatin in Hypercholesterolemia, sponsored by Organon and Co. Completed. Open to participants aged 10 Years to 17 Years. Per ClinicalTrials.gov, last updated 2022-02-08.

Sponsored by Organon and Co · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
248
Allocation
Randomized
Ages
10 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 98 studies testing ezetimibe in Hypercholesterolemia — 3 open to participants now, 4 under way, 1 of them phase 3. Ezetimibe · Hypercholesterolemia.

Enrollment
33rd of 97
248 · median 148
Started
2005
with 13 others
Phase 3
50 of 98
1 open now
Registered
7th of 98
by date
Lead sponsor
55 of 98
Organon and Co

Among the 98 studies testing ezetimibe in Hypercholesterolemia, this one is the 33rd largest by enrollment of the 97 interventional ones that give a count, is one of 14 that started in 2005, is one of 50 in phase 3, and was the 7th registered.

Hypercholesterolemia

1,179 studies on the registry are indexed under Hypercholesterolemia; 96 are open to participants now.

Browse Hypercholesterolemia studies →

Open to participants now

3 of the 98 studies testing ezetimibe in Hypercholesterolemia are open now, in 5 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About ezetimibe

Ezetimibe: first FDA approval 2002 (ZETIA), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 57 Hypercholesterolemia studies recruiting now, 25 (44%) set no upper age limit and 20 (35%) stop at 75 or younger; 10 take children under 18; 11 take healthy volunteers.

This study: 10 Years to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 98 studies testing ezetimibe in Hypercholesterolemia, or all of them as a file.
02

Study summary

This is a randomized, double-blind, controlled, parallel-group, multicenter, Phase-3 study to evaluate the efficacy and safety of ezetimibe with simvastatin taken alone in subjects ages 10-17 years with Heterozygous Familial Hypercholesterolemia.

Read the detailed description

This study consisted of 3 distinct periods. In Period 1, subjects received daily treatment for 6 weeks as part of either the ezetimibe with simvastatin group or part of the simvastatin monotherapy group. Subjects in the ezetimibe with simvastatin group received one of three treatments: coadministration of ezetimibe 10 mg/day plus simvastatin 10 mg/day, 20 mg/day, or 40 mg/day. Subjects in the simvastatin monotherapy group received one of three treatments: ezetimibe placebo plus simvastatin 10 mg/day, 20 mg/day, or 40 mg/day. The primary and key secondary efficacy analysis were based on the evaluations performed during Period 1 and were presented as data for subjects pooled from either the ezetimibe with simvastatin treatment groups compared with data for subjects pooled from the simvastatin monotherapy treatment groups.

In Period 2, subjects received ezetimibe 10 mg/day plus simvastatin 40 mg/day or ezetimibe placebo plus simvastatin 40 mg/day for 27 additional weeks maintaining the same treatment assignment (coadministration vs monotherapy) as in Period 1.

In Period 3, all subjects received ezetimibe 10 mg/day plus open-label simvastatin daily for 20 weeks.

03

Conditions studied

  • Hypercholesterolemia

Keywords

  • cholesterol
  • drugs
  • hypercholesterolemia
  • adolescent
  • randomized controlled trials
04

Who can participate

Ages eligible
10 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adolescent (ages 10 - 17 years) boys or girls weighing at least 88 lbs (40 kg).
  • Subjects must have high cholesterol (low density lipoprotein cholesterol [LDL-C] more than 159 mg/dL or 4.1 mmol/L) and a family history of high cholesterol.

Exclusion criteria

Exclusion Criteria:

  • Subjects diagnosed with delayed puberty.
  • Subjects who are sensitive to simvastatin and/or ezetimibe.
  • Subjects who drink alcohol excessively or who have a history of alcohol or drug abuse within the past 2 years.
  • Subjects who are known to be positive, are undergoing LDL apheresis or plasma apheresis, or have had a partial ileal bypass.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
248 participants (actual)

Study arms

  • Experimental
    Pooled subjects who received ezetimibe with simvastatin

    Pooled subjects who received ezetimibe 10 mg plus simvastatin 10 mg, simvastatin 20 mg, or simvastatin 40 mg

    Drug: ezetimibe with simvastatin

  • Active comparator
    Pooled subjects who received simvastatin monotherapy

    Pooled subjects who received ezetimibe matching placebo plus simvastatin 10 mg, simvastatin 20 mg, or simvastatin 40 mg

    Drug: simvastatin

Interventions

  • Drugezetimibe with simvastatin

    Drug pages: Ezetimibe · Simvastatin

    Ezetimibe 10 mg plus simvastatin 10 mg once a day for six weeks, or Ezetimibe 10 mg plus simvastatin 20 mg once a day for six weeks, or Ezetimibe 10 mg plus simvastatin 40 mg once a day for six weeks

  • Ezetimibe matching placebo plus simvastatin 10 mg once a day for six weeks, or Ezetimibe matching placebo plus simvastatin 20 mg once a day for six weeks, or Ezetimibe matching placebo plus simvastatin 40 mg once a day for six weeks

06

What researchers measure

Primary outcomes

  1. Percent Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C)

    Least squares mean percent change from Baseline in LDL-C at the end of Step 1 (Week 6) in the pooled groups who received ezetimibe plus simvastatin compared with pooled groups who received simvastatin monotherapy

    Time frame: baseline to 6 weeks

Secondary outcomes

  1. Percent Change From Baseline in Total Cholesterol (TC)

    Time frame: baseline to 6 weeks

  2. Percent Change From Baseline in Non High-density Lipoprotein Cholesterol (Non HDL-C)

    Time frame: baseline to 6 weeks

  3. Percent Change From Baseline in Triglycerides (TG)

    Time frame: baseline to 6 weeks

  4. Percent Change From Baseline in Apolipoprotein B (Apo B)

    Time frame: baseline to 6 weeks

  5. Percent Change From Baseline in HDL-C

    Time frame: baseline to 6 weeks

07

Results

Posted Feb 11, 2010

Participant flow

Start Period1 to End Period1 (Week 1-6)
Participant flow — Start Period1 to End Period1 (Week 1-6)
MilestoneEzetimibe/Simvastatin 10/10Ezetimibe/Simvastatin 10/20Ezetimibe/Simvastatin 10/40Ezetimibe Matching Placebo/ Simvastatin 10Ezetimibe Matching Placebo/ Simvastatin 20Ezetimibe Matching Placebo/ Simvastatin 40Long-term Experience Ezetimbe/Simvastatin
Started4340434040420
Completed4339413939400
Not completed0121120
Withdrew: Adverse event0110010
Withdrew: Lost to follow-up0000010
Withdrew: Protocol violation0001000
Withdrew: Withdrawal by subject0010100
Start Period2 to End Period2 (Week 7-33)
Participant flow — Start Period2 to End Period2 (Week 7-33)
MilestoneEzetimibe/Simvastatin 10/10Ezetimibe/Simvastatin 10/20Ezetimibe/Simvastatin 10/40Ezetimibe Matching Placebo/ Simvastatin 10Ezetimibe Matching Placebo/ Simvastatin 20Ezetimibe Matching Placebo/ Simvastatin 40Long-term Experience Ezetimbe/Simvastatin
Started00122001180
Completed00114001130
Not completed0080050
Withdrew: Adverse event0020000
Withdrew: Laboratory adverse event0030010
Withdrew: Lost to follow-up0010000
Withdrew: Withdrawal by subject0010030
Withdrew: Protocol violation0010010
Start Period3 to End Period3(Week 34-53)
Participant flow — Start Period3 to End Period3(Week 34-53)
MilestoneEzetimibe/Simvastatin 10/10Ezetimibe/Simvastatin 10/20Ezetimibe/Simvastatin 10/40Ezetimibe Matching Placebo/ Simvastatin 10Ezetimibe Matching Placebo/ Simvastatin 20Ezetimibe Matching Placebo/ Simvastatin 40Long-term Experience Ezetimbe/Simvastatin
Started000000228
Completed000000222
Not completed0000006
Withdrew: Lost to follow-up0000001
Withdrew: Withdrawal by subject0000003
Withdrew: Subject moved0000001
Withdrew: Protocol violation0000001

Outcome measures

PrimaryPercent Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C)

Least squares mean percent change from Baseline in LDL-C at the end of Step 1 (Week 6) in the pooled groups who received ezetimibe plus simvastatin compared with pooled groups who received simvastatin monotherapy

Time frame:
baseline to 6 weeks
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C)
percent changePooled Subjects Who Received Ezetimibe With SimvastatinPooled Subjects Who Received Simvastatin Monotherapy
Percent Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C)-49.45 ± 1.19-34.43 ± 1.22
Statistical analysis
  • Pooled Subjects Who Received Ezetimibe With Simvastatin vs Pooled Subjects Who Received Simvastatin Monotherapy · ANOVA · p = <0.01
SecondaryPercent Change From Baseline in Total Cholesterol (TC)
Time frame:
baseline to 6 weeks
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Total Cholesterol (TC)
percent changePooled Subjects Who Received Ezetimibe With SimvastatinPooled Subjects Who Received Simvastatin Monotherapy
Percent Change From Baseline in Total Cholesterol (TC)-38.23 ± .96-26.28 ± .99
Statistical analysis
  • Pooled Subjects Who Received Simvastatin Monotherapy · ANOVA · p = <0.01
SecondaryPercent Change From Baseline in Non High-density Lipoprotein Cholesterol (Non HDL-C)
Time frame:
baseline to 6 weeks
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Non High-density Lipoprotein Cholesterol (Non HDL-C)
percent changePooled Subjects Who Received Ezetimibe With SimvastatinPooled Subjects Who Received Simvastatin Monotherapy
Percent Change From Baseline in Non High-density Lipoprotein Cholesterol (Non HDL-C)-46.84 ± 1.13-32.68 ± 1.16
Statistical analysis
  • Pooled Subjects Who Received Ezetimibe With Simvastatin vs Pooled Subjects Who Received Simvastatin Monotherapy · ANOVA · p = <0.01
SecondaryPercent Change From Baseline in Triglycerides (TG)
Time frame:
baseline to 6 weeks
Reported as:
Median · percent change
Percent Change From Baseline in Triglycerides (TG)
percent changePooled Subjects Who Received Ezetimibe With SimvastatinPooled Subjects Who Received Simvastatin Monotherapy
Percent Change From Baseline in Triglycerides (TG)-16.56 ± 30.26-12.28 ± 31.49
Statistical analysis
  • Pooled Subjects Who Received Ezetimibe With Simvastatin vs Pooled Subjects Who Received Simvastatin Monotherapy · non-parametric model · p = .48
SecondaryPercent Change From Baseline in Apolipoprotein B (Apo B)
Time frame:
baseline to 6 weeks
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Apolipoprotein B (Apo B)
percent changePooled Subjects Who Received Ezetimibe With SimvastatinPooled Subjects Who Received Simvastatin Monotherapy
Percent Change From Baseline in Apolipoprotein B (Apo B)-38.92 ± 1.1-26.69 ± 1.11
Statistical analysis
  • Pooled Subjects Who Received Ezetimibe With Simvastatin vs Pooled Subjects Who Received Simvastatin Monotherapy · ANOVA · p = <0.01
SecondaryPercent Change From Baseline in HDL-C
Time frame:
baseline to 6 weeks
Reported as:
Least squares mean · percent change
Percent Change From Baseline in HDL-C
percent changePooled Subjects Who Received Ezetimibe With SimvastatinPooled Subjects Who Received Simvastatin Monotherapy
Percent Change From Baseline in HDL-C6.58 ± 1.166.47 ± 1.19
Statistical analysis
  • Pooled Subjects Who Received Ezetimibe With Simvastatin vs Pooled Subjects Who Received Simvastatin Monotherapy · ANOVA · p = .95

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Ezetimibe With Simvastatin—4/126 (3.2%)58/126 (46%)
Simvastatin Monotherapy—1/122 (0.8%)59/122 (48.4%)
Long-term Coadministration of Ezetimibe With Simvastatin—3/227 (1.3%)42/227 (18.5%)
Most frequent serious events
Most frequent serious events
EventEzetimibe With SimvastatinSimvastatin MonotherapyLong-term Coadministration of Ezetimibe With Simvastatin
Accidental overdoseInjury, poisoning and procedural complications0/1261/1220/227
PyrexiaGeneral disorders1/1260/1220/227
Arthritis bacterialInfections and infestations1/1260/1220/227
TonsillitisInfections and infestations1/1260/1220/227
TendonitisMusculoskeletal and connective tissue disorders1/1260/1220/227
EncephalopathyNervous system disorders1/1260/1220/227
Pilonidal cystInfections and infestations0/1260/1221/227
Subcutaneous abscessInfections and infestations0/1260/1221/227
OverdoseInjury, poisoning and procedural complications0/1260/1221/227
Most frequent other events
Most frequent other events
EventEzetimibe With SimvastatinSimvastatin MonotherapyLong-term Coadministration of Ezetimibe With Simvastatin
NasopharyngitisInfections and infestations27/12627/12216/227
HeadacheNervous system disorders16/12616/1226/227
InfluenzaInfections and infestations8/12612/12212/227
AcneSkin and subcutaneous tissue disorders4/1269/1223/227
DiarrhoeaGastrointestinal disorders9/1263/1222/227
CoughRespiratory, thoracic and mediastinal disorders4/1268/1225/227
NauseaGastrointestinal disorders8/1264/1222/227
MyalgiaMusculoskeletal and connective tissue disorders7/1261/1220/227

Baseline characteristics

Age, Continuous
Age, Continuous(years)Pooled Subjects Who Received Ezetimibe With SimvastatinPooled Subjects Who Received Simvastatin MonotherapyTotal
Mean14.0 ± 1.914.3 ± 1.814.2 ± 1.9
Sex: Female, Male
Sex: Female, Male(Participants)Pooled Subjects Who Received Ezetimibe With SimvastatinPooled Subjects Who Received Simvastatin MonotherapyTotal
Female5353106
Male7369142
08

Study locations

No study locations are listed for this record.

09

References and documents

Publications

  • van der Graaf A, Cuffie-Jackson C, Vissers MN, Trip MD, Gagne C, Shi G, Veltri E, Avis HJ, Kastelein JJ. Efficacy and safety of coadministration of ezetimibe and simvastatin in adolescents with heterozygous familial hypercholesterolemia. J Am Coll Cardiol. 2008 Oct 21;52(17):1421-9. doi: 10.1016/j.jacc.2008.09.002. PubMed 18940534 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2005, a primary completion of Jun 2007 and a completion of Jun 2007. It does not say whether these dates are actual or estimated.

Results were first posted in Feb 2010, 2 years 8 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 9, 2005
First posted
Aug 11, 2005
Start
Aug 2005
Primary completionActual
Jun 2007
CompletionActual
Jun 2007
Results first posted
Feb 11, 2010
Last update
Feb 8, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 8, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00129402
Lead sponsor
Organon and Co
Responsible party
Sponsor
First posted
Aug 11, 2005
Start date
Aug 2005
Primary completion
Jun 2007
Completion
Jun 2007
Results posted
Feb 11, 2010
Last update
Feb 8, 2022
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Ezetimibe · Simvastatin

Start the discussion